Literature DB >> 19050584

Identifying mechanisms for therapeutic intervention in chordoma: c-Met oncoprotein.

Elena Ostroumov1, Christopher J Hunter.   

Abstract

STUDY
DESIGN: A human sacral chordoma cell line, CCL3, was established and in vitro characterization of c-Met oncoprotein in chordoma cells was performed.
OBJECTIVE: Determination of whether c-Met plays an important role in chordoma's malignancy. SUMMARY OF BACKGROUND DATA: Chordomas are malignant life-threatening tumors that arise from the remnants of the notochord. c-Met is an oncoprotein that is expressed by a variety of solid tumors, including chordomas, and HGF is its high affinity ligand. In the present study, we investigated c-Met and HGF expression, localization, and function in human chordoma cells.
METHODS: SDS-PAGE, Western blotting, immunofluorescence techniques, and cell migration functional assays were used to asses c-Met and HGF expression, localization, and functional activity.
RESULTS: Intracellular protein tyrosine phosphorylation was enhanced on HGF binding, and an increase in the amount of 50 kDa alpha-chain of c-Met was detected in HGF-stimulated cells. Immunostaining of c-Met and HGF revealed membrane/cytoplasmic localization in nonstimulated cells, and perinuclear colocalization in HGF-stimulated cells. Positive chemotactic and migration activity in response to HGF was also demonstrated.
CONCLUSION: Our data supports our hypothesis that the c-Met oncoprotein plays a leading role in the metastatic process in chordomas, and that a c-Met-HGF pair is involved in chordoma malignancy. Taking into consideration the very limited treatment options and an extremely poor prognosis for the chordoma patients, our results are a valuable and promising addition to the current situation in managing chordomas.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19050584     DOI: 10.1097/BRS.0b013e31817e2d1e

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  15 in total

1.  Establishment and characterization of a primary human chordoma xenograft model.

Authors:  I-Mei Siu; Vafi Salmasi; Brent A Orr; Qi Zhao; Zev A Binder; Christine Tran; Masaru Ishii; Gregory J Riggins; Christine L Hann; Gary L Gallia
Journal:  J Neurosurg       Date:  2012-01-27       Impact factor: 5.115

2.  Gain of chromosome 7 by chromogenic in situ hybridization (CISH) in chordomas is correlated to c-MET expression.

Authors:  Beatriz A Walter; Maria Begnami; Vladimir A Valera; Mariarita Santi; Elisabeth J Rushing; Martha Quezado
Journal:  J Neurooncol       Date:  2010-07-10       Impact factor: 4.130

Review 3.  Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review.

Authors:  Simon G Launay; Bruno Chetaille; Fanny Medina; Delphine Perrot; Serge Nazarian; Jérôme Guiramand; Laurence Moureau-Zabotto; François Bertucci
Journal:  BMC Cancer       Date:  2011-10-04       Impact factor: 4.430

Review 4.  Systemic therapy options for unresectable and metastatic chordomas.

Authors:  Silvia Stacchiotti; Paolo Giovanni Casali
Journal:  Curr Oncol Rep       Date:  2011-08       Impact factor: 5.075

5.  Immunohistochemical expression of receptor tyrosine kinase PDGFR-α, c-Met, and EGFR in skull base chordoma.

Authors:  R Akhavan-Sigari; M Abili; M R Gaab; V Rohde; N Zafar; P Emami; H Ostertag
Journal:  Neurosurg Rev       Date:  2014-10-17       Impact factor: 3.042

6.  Generation of a patient-derived chordoma xenograft and characterization of the phosphoproteome in a recurrent chordoma.

Authors:  Jason M Davies; Aaron E Robinson; Cynthia Cowdrey; Praveen V Mummaneni; Gregory S Ducker; Kevan M Shokat; Andrew Bollen; Byron Hann; Joanna J Phillips
Journal:  J Neurosurg       Date:  2013-11-29       Impact factor: 5.115

Review 7.  MicroRNA-mediated gene regulations in human sarcomas.

Authors:  Subbaya Subramanian; Reena V Kartha
Journal:  Cell Mol Life Sci       Date:  2012-08-25       Impact factor: 9.261

8.  Chemotherapy of skull base chordoma tailored on responsiveness of patient-derived tumor cells to rapamycin.

Authors:  Lucia Ricci-Vitiani; Daniele Runci; Quintino Giorgio D'Alessandris; Tonia Cenci; Maurizio Martini; Federico Bianchi; Giulio Maira; Louis Stancato; Ruggero De Maria; Luigi Maria Larocca; Roberto Pallini
Journal:  Neoplasia       Date:  2013-07       Impact factor: 5.715

9.  Converging paths to progress for skull base chordoma: Review of current therapy and future molecular targets.

Authors:  Salvatore Di Maio; Esther Kong; Stephen Yip; Robert Rostomily
Journal:  Surg Neurol Int       Date:  2013-06-01

10.  Immune Myocarditis Overlapping With Myasthenia Gravis Due to Anti-PD-1 Treatment for a Chordoma Patient: A Case Report and Literature Review.

Authors:  Shujing Liang; Jingxian Yang; Yun Lin; Tong Li; Wenrong Zhao; Jun Zhao; Chunyan Dong
Journal:  Front Immunol       Date:  2021-07-08       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.